Upjohn Company Profile
✉ Email this page to a colleague
What is the competitive landscape for UPJOHN, and when can generic versions of UPJOHN drugs launch?
UPJOHN has thirteen approved drugs.
There are three US patents protecting UPJOHN drugs.
There are thirty-three patent family members on UPJOHN drugs in thirty-three countries and thirty-nine supplementary protection certificates in thirteen countries.
Drugs and US Patents for Upjohn
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Upjohn | LYRICA | pregabalin | CAPSULE;ORAL | 021446-005 | Dec 30, 2004 | AB | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | ||||
Upjohn | XANAX | alprazolam | TABLET;ORAL | 018276-003 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ||||
Upjohn | LYRICA CR | pregabalin | TABLET, EXTENDED RELEASE;ORAL | 209501-003 | Oct 11, 2017 | AB | RX | Yes | Yes | 9,144,559*PED | ⤷ Subscribe | Y | ⤷ Subscribe | ||
Upjohn | XANAX XR | alprazolam | TABLET, EXTENDED RELEASE;ORAL | 021434-001 | Jan 17, 2003 | AB | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Upjohn
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Upjohn | DETROL LA | tolterodine tartrate | CAPSULE, EXTENDED RELEASE;ORAL | 021228-002 | Dec 22, 2000 | 6,630,162*PED | ⤷ Subscribe |
Upjohn | LIPITOR | atorvastatin calcium | TABLET;ORAL | 020702-002 | Dec 17, 1996 | 5,686,104*PED | ⤷ Subscribe |
Upjohn | LIPITOR | atorvastatin calcium | TABLET;ORAL | 020702-003 | Dec 17, 1996 | 5,686,104*PED | ⤷ Subscribe |
Upjohn | LIPITOR | atorvastatin calcium | TABLET;ORAL | 020702-003 | Dec 17, 1996 | 6,126,971*PED | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for UPJOHN drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 25 mg and 50 mg | ➤ Subscribe | 2006-09-27 |
➤ Subscribe | Extended-release Capsules | 2 mg and 4 mg | ➤ Subscribe | 2007-07-30 |
➤ Subscribe | Capsules | 50 mg | ➤ Subscribe | 2008-03-21 |
➤ Subscribe | Oral Solution | 20 mg/mL | ➤ Subscribe | 2010-05-19 |
➤ Subscribe | Extended-release Tablets | 82.5 mg and 165 mg | ➤ Subscribe | 2018-02-02 |
➤ Subscribe | Extended-release Tablets | 82.5 mg and 165 mg | ➤ Subscribe | 2018-02-02 |
➤ Subscribe | Tablets | 20 mg and 40 mg | ➤ Subscribe | 2010-03-29 |
➤ Subscribe | Extended-release Tablets | 37.5 mg, 75 mg and 150 mg | ➤ Subscribe | 2007-05-03 |
➤ Subscribe | Capsules | 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg | ➤ Subscribe | 2008-12-30 |
➤ Subscribe | Extended-release Tablets | 330 mg | ➤ Subscribe | 2018-01-29 |
➤ Subscribe | Extended-release Tablets | 330 mg | ➤ Subscribe | 2018-01-29 |
International Patents for Upjohn Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Eurasian Patent Organization | 012377 | ⤷ Subscribe |
South Korea | 20080059427 | ⤷ Subscribe |
Netherlands | 2000281 | ⤷ Subscribe |
Peru | 20070693 | ⤷ Subscribe |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Upjohn Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0364417 | C970039 | Netherlands | ⤷ Subscribe | PRODUCT NAME: [1R-[1 ALPHA (Z),2 BETA(R*),3 ALPHA,5ALPHA]]-7-[3,5-DIHYDROXY-2-(3-HYDROXY-5- FENYLPENTYL)CYCLOPENTYL]-5-HEPTEENZUUR, DESGEWENST IN DE VORM VAN EEN ZOUT OF EEN ESTER, IN HET BIJZONDER LATANOPROSTUM; NAT. REGISTRATION NO/DATE: RVG 21304 19970610; FIRST REGISTRATION: SE 12716 19960718 |
0325571 | C980020 | Netherlands | ⤷ Subscribe | PRODUCT NAME: TOLTERODINE, DESGEWENST IN DE VORM VAN EEN ZOUT MET EEN FYSIOLO GISCH ACCEPTABEL ZUUR, IN HET BIJZONDER TOLTERODINE L-TARTRAAT; NAT. REGISTRATION NO/DATE: RVG 22148, RVG 22149 19980217; FIRST REGISTRATION: SE 13475, 13476 19970905 |
0720599 | 122014000088 | Germany | ⤷ Subscribe | PRODUCT NAME: EZETIMIB ODER PHARMAZEUTISCH ANNEHMBARE SALZE DAVON IN KOMBINATION MIT ATORVASTATIN ODER PHARMAZEUTISCH ANNEHMBARE SALZE DAVON, INSBESONDERE ATORVASTATIN ALS ATORVASTATINCALCIUMTRIHYDRAT; NAT. REGISTRATION NO/DATE: 90223.00.00 20141113; FIRST REGISTRATION: FRANKREICH CIS: 6 928 917 6 20140912 |
3461484 | 2021C/515 | Belgium | ⤷ Subscribe | PRODUCT NAME: ROCLANDA - LATANOPROST / NETARSUDIL; AUTHORISATION NUMBER AND DATE: EU/1/20/1502 20210108 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.